Clear Search sequence regions


Sizes of these terms reflect their relevance to your search.

Growth hormone (GH) treatment has been an established therapy for GH deficiency (GHD) in children and adults for more than three decades. Numerous studies have shown that GH treatment improves height, body composition, bone density, cardiovascular risk factors, physical fitness and quality of life and that the treatment has few side effects. Initially GH was given as intramuscular injections three times per week, but daily subcutaneous injections were shown to be more effective and less inconvenient and the daily administration has been used since its introduction in the 1980s. However, despite ongoing improvements in injection device design, daily subcutaneous injections remain inconvenient, painful and distressing for many patients, leading to noncompliance, reduced efficacy and increased health care costs. To address these issues a variety of long-acting formulations of GH have been developed. In this review we present the current status of long-acting GH preparations and discuss the specific issues related to their development. Copyright © 2015 Elsevier Ltd. All rights reserved.

Citation

Charlotte Høybye, Pinchas Cohen, Andrew R Hoffman, Richard Ross, Beverly M K Biller, Jens Sandahl Christiansen, Growth Hormone Research Society. Status of long-acting-growth hormone preparations--2015. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. 2015 Oct;25(5):201-6

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 26187188

View Full Text